Mark Greenwald
Division
Substance Abuse Research Division
Research Interests
Pharmacological, environmental and individual difference determinants of drug-seeking/use behavior (primary endpoint) and neural processes (measured with in vivo imaging methods) related to these behaviors.
Disease/Disorder
Opioid, cocaine, marijuana, nicotine, and alcohol use disorders.
Species
Human
Methods
PET (opioid and dopamine), 1H spectroscopy, fMRI and EEG.
Key Collaborators
Leslie Lundahl, David Ledgerwood and Cynthia Arfken (substance use disorders, HIV/AIDS); Jeffrey Stanley (1H spectroscopy); Vaibhav Diwadkar (fMRI, learning/memory); Sylvie Naar-King and Paul Burghardt (stress, physical activity and obesity); Terrance Albrecht, Ann Schwartz and Jennifer Beebe-Dimmer (KCI: chemotherapy-induced peripheral neuropathy); Timothy Roehrs (Henry Ford: EEG, sleep, pain); Margit Burmeister (Univ. of Michigan: pharmacogenetics).
Publications
Recent university news spotlights
- Clinical trial led by Wayne State Professor Mark Greenwald, Ph.D., proves neurostimulation device to treat opioid use disorder is effective
- National Institutes of Health awards Wayne State $1.19 million for addiction neuroscience predoctoral training
- Detroit takes aim to transform drug addiction
- Wayne State’s Dr. Mark Greenwald contributing to $16.6 million drug development project for treatment of opioid use disorder
- Provost’s Social & Behavioral Determinants of Health Steering Committee announces this year’s five awardees